Clinical Trials Logo

Primary Immunodeficiency Disease clinical trials

View clinical trials related to Primary Immunodeficiency Disease.

Filter by:

NCT ID: NCT06150833 Not yet recruiting - Clinical trials for Primary Immunodeficiency Disease

Efficacy and Safety and Pharmacokinetics of Boya IVIG

Boya
Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

To evaluate the safety, efficacy and pharmacokinetic properties of Boya's IVIG preparation in participants with PID aged less than 60 years and more than 6 years.

NCT ID: NCT06089122 Not yet recruiting - Clinical trials for Primary Immunodeficiency Disease

Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG

Imunoforte
Start date: April 2024
Phase: Phase 3
Study type: Interventional

To evaluate the safety, efficacy, and pharmacokinetic properties of Shu Yang intravenous immune globulin in patients with primary immune deficiency aged less than 60 years. The main benefit of IVIG is to help the body fight against a large variety of infections generally associated with morbidity and mortality in patients with primary immunodeficiency diseases, particularly in CVID and XLA. In addition, a decrease in the number of infections, a reduction in medications and hospitalizations, and a better quality of life are expected. Throughout treatment, approximately one-fourth of persons may experience a side effect. These are usually mild or bothersome but not dangerous. Very rarely, more serious side effects like allergic reactions or low blood counts (anemia) can occur. One of the most common side effects is headache. Other side effects include chills, fever, flushing, flu-like muscle pains or joint pains, feeling tired, nausea, vomiting, and rash. For the most part, these reactions typically happen with the first dose of IVIG or because change to a different brand of IVIG. All IVIG products have similar warnings and contraindications, such as the potential for renal failure, thrombotic events, aseptic meningitis, hemolysis, and anaphylactic reactions.

NCT ID: NCT04944979 Recruiting - Clinical trials for Primary Immunodeficiency Disease

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)

KIDCARES10
Start date: March 31, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess efficacy, safety and pharmacokinetics of Kedrion Immunoglobulin 10% (KIg10) in pediatric patients with Primary Immunodeficiency Disease (PID).

NCT ID: NCT04842643 Completed - Clinical trials for Primary Immunodeficiency Disease

An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease

Start date: April 27, 2021
Phase: Phase 3
Study type: Interventional

This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study. The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.

NCT ID: NCT03961009 Completed - Clinical trials for Primary Immunodeficiency Disease

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

CARES10
Start date: April 30, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).

NCT ID: NCT03677557 Recruiting - Clinical trials for Primary Immunodeficiency Disease

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Start date: September 19, 2018
Phase: Phase 4
Study type: Interventional

Patients with primary or secondary immunodeficiency disease who have developed adverse reactions to products available on the market such as Cuvitru® (Shire), Hizentra® (CSL Behring) or 10% Gammunex® (Grifols), may benefit from utilizing 16.5% Cutaquig® (Octapharma).

NCT ID: NCT03252548 Not yet recruiting - Clinical trials for Primary Immunodeficiency Disease

Pediatric Primary Immunodeficiency Disease (PID) in China

Start date: January 2018
Phase: N/A
Study type: Observational

This study is a prospective cohort study of children diagnosed with primary immunodeficiency disease (PID). The aim is to investigate the clinical characteristics and prognosis of PID in Chinese children.

NCT ID: NCT02810444 Completed - Clinical trials for Primary Immunodeficiency Disease

Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Start date: October 4, 2016
Phase: Phase 3
Study type: Interventional

This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)

NCT ID: NCT02627300 Completed - Clinical trials for Primary Immunodeficiency Disease

Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial

Start date: March 2016
Phase: Phase 3
Study type: Interventional

Patients will be followed from the time of completion of the SCGAM 01 trial until octanorm becomes commercially available in the USA, until the sponsor decides to terminate the trial, or until a patient's treatment duration of 2.5 years is reached (whichever occurs first).

NCT ID: NCT01150240 Enrolling by invitation - Clinical trials for Primary Immunodeficiency Disease

Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland

Start date: October 2006
Phase: N/A
Study type: Observational

A Swiss national, multi-centre, online patient and research database will be created, using the existing ESID database server system. This database contains disease-specific data from patients with primary (inborn) immunodeficiency diseases (PID).